These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

547 related items for PubMed ID: 17287272

  • 21. Structural and Thermodynamic Basis of Epitope Binding by Neutralizing and Nonneutralizing Forms of the Anti-HIV-1 Antibody 4E10.
    Rujas E, Gulzar N, Morante K, Tsumoto K, Scott JK, Nieva JL, Caaveiro JM.
    J Virol; 2015 Dec; 89(23):11975-89. PubMed ID: 26378169
    [Abstract] [Full Text] [Related]

  • 22. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.
    Alam SM, McAdams M, Boren D, Rak M, Scearce RM, Gao F, Camacho ZT, Gewirth D, Kelsoe G, Chen P, Haynes BF.
    J Immunol; 2007 Apr 01; 178(7):4424-35. PubMed ID: 17372000
    [Abstract] [Full Text] [Related]

  • 23. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.
    Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G, Forthal DN, Koff WC, Poignard P, Watkins DI, Burton DR.
    J Virol; 2010 Feb 01; 84(3):1302-13. PubMed ID: 19906907
    [Abstract] [Full Text] [Related]

  • 24. Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications.
    Bryson S, Julien JP, Hynes RC, Pai EF.
    J Virol; 2009 Nov 01; 83(22):11862-75. PubMed ID: 19740978
    [Abstract] [Full Text] [Related]

  • 25. Modulation of nonneutralizing HIV-1 gp41 responses by an MHC-restricted TH epitope overlapping those of membrane proximal external region broadly neutralizing antibodies.
    Zhang J, Alam SM, Bouton-Verville H, Chen Y, Newman A, Stewart S, Jaeger FH, Montefiori DC, Dennison SM, Haynes BF, Verkoczy L.
    J Immunol; 2014 Feb 15; 192(4):1693-706. PubMed ID: 24465011
    [Abstract] [Full Text] [Related]

  • 26. Structure-based design of a protein immunogen that displays an HIV-1 gp41 neutralizing epitope.
    Stanfield RL, Julien JP, Pejchal R, Gach JS, Zwick MB, Wilson IA.
    J Mol Biol; 2011 Dec 02; 414(3):460-76. PubMed ID: 22033480
    [Abstract] [Full Text] [Related]

  • 27. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.
    Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, Katinger H.
    AIDS Res Hum Retroviruses; 2001 Dec 10; 17(18):1757-65. PubMed ID: 11788027
    [Abstract] [Full Text] [Related]

  • 28. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.
    Shen X, Parks RJ, Montefiori DC, Kirchherr JL, Keele BF, Decker JM, Blattner WA, Gao F, Weinhold KJ, Hicks CB, Greenberg ML, Hahn BH, Shaw GM, Haynes BF, Tomaras GD.
    J Virol; 2009 Apr 10; 83(8):3617-25. PubMed ID: 19193787
    [Abstract] [Full Text] [Related]

  • 29. Estimating the probability of polyreactive antibodies 4E10 and 2F5 disabling a gp41 trimer after T cell-HIV adhesion.
    Hu B, Liao HX, Alam SM, Goldstein B.
    PLoS Comput Biol; 2014 Jan 10; 10(1):e1003431. PubMed ID: 24499928
    [Abstract] [Full Text] [Related]

  • 30. Synthesis and analysis of the membrane proximal external region epitopes of HIV-1.
    Ingale S, Gach JS, Zwick MB, Dawson PE.
    J Pept Sci; 2010 Dec 10; 16(12):716-22. PubMed ID: 21104968
    [Abstract] [Full Text] [Related]

  • 31. Selection and immune recognition of HIV-1 MPER mimotopes.
    Wieczorek L, Peachman K, Steers N, Schoen J, Rao M, Polonis V, Rao V.
    Virology; 2020 Nov 10; 550():99-108. PubMed ID: 32980676
    [Abstract] [Full Text] [Related]

  • 32. Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface.
    Song L, Sun ZY, Coleman KE, Zwick MB, Gach JS, Wang JH, Reinherz EL, Wagner G, Kim M.
    Proc Natl Acad Sci U S A; 2009 Jun 02; 106(22):9057-62. PubMed ID: 19458040
    [Abstract] [Full Text] [Related]

  • 33. Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6.
    Bryson S, Julien JP, Isenman DE, Kunert R, Katinger H, Pai EF.
    J Mol Biol; 2008 Oct 17; 382(4):910-9. PubMed ID: 18692506
    [Abstract] [Full Text] [Related]

  • 34. Anti-HIV-1 antibodies 2F5 and 4E10 interact differently with lipids to bind their epitopes.
    Franquelim HG, Chiantia S, Veiga AS, Santos NC, Schwille P, Castanho MA.
    AIDS; 2011 Feb 20; 25(4):419-28. PubMed ID: 21245727
    [Abstract] [Full Text] [Related]

  • 35. Binding of anti-membrane-proximal gp41 monoclonal antibodies to CD4-liganded and -unliganded human immunodeficiency virus type 1 and simian immunodeficiency virus virions.
    Rathinakumar R, Dutta M, Zhu P, Johnson WE, Roux KH.
    J Virol; 2012 Feb 20; 86(3):1820-31. PubMed ID: 22090143
    [Abstract] [Full Text] [Related]

  • 36. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.
    Montero M, van Houten NE, Wang X, Scott JK.
    Microbiol Mol Biol Rev; 2008 Mar 20; 72(1):54-84, table of contents. PubMed ID: 18322034
    [Abstract] [Full Text] [Related]

  • 37. Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region.
    Gray ES, Madiga MC, Moore PL, Mlisana K, Abdool Karim SS, Binley JM, Shaw GM, Mascola JR, Morris L.
    J Virol; 2009 Nov 20; 83(21):11265-74. PubMed ID: 19692477
    [Abstract] [Full Text] [Related]

  • 38. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.
    Klein JS, Gnanapragasam PN, Galimidi RP, Foglesong CP, West AP, Bjorkman PJ.
    Proc Natl Acad Sci U S A; 2009 May 05; 106(18):7385-90. PubMed ID: 19372381
    [Abstract] [Full Text] [Related]

  • 39. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
    Chakrabarti BK, Pancera M, Phogat S, O'Dell S, McKee K, Guenaga J, Robinson J, Mascola J, Wyatt RT.
    AIDS Res Hum Retroviruses; 2011 Aug 05; 27(8):877-87. PubMed ID: 21158699
    [Abstract] [Full Text] [Related]

  • 40. Exposure of the HIV-1 broadly neutralizing antibody 10E8 MPER epitope on the membrane surface by gp41 transmembrane domain scaffolds.
    Oakes V, Torralba J, Rujas E, Nieva JL, Domene C, Apellaniz B.
    Biochim Biophys Acta Biomembr; 2018 Jun 05; 1860(6):1259-1271. PubMed ID: 29477358
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.